Cargando…

The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China

For patients with pretreated advanced non-small cell lung cancer (NSCLC), more effective treatments are unmet. We conducted a study to explore the optimal treatment schedule of nanoparticle albumin bound paclitaxel (Nab-PTX) as a second line or later treatment for advanced NSCLC patients in China. N...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xing, Puyuan, Zhu, Yixiang, Shan, Ling, Chen, Sipeng, Hao, Xuezhi, Li, Junling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675645/ https://www.ncbi.nlm.nih.gov/pubmed/29152093 http://dx.doi.org/10.18632/oncotarget.21103

Ejemplares similares

Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen
por: Hao, Xuezhi, et al.
Publicado: (2020)

Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer
por: Anzai, Masaki, et al.
Publicado: (2017)

Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression
por: Xu, Ziyi, et al.
Publicado: (2022)

Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer
por: Sasaki, Yasutsuna, et al.
Publicado: (2014)

Weekly nanoparticle albumin-bound paclitaxel and paclitaxel for relapsed small cell lung cancer: A retrospective observational study
por: Oi, Hajime, et al.
Publicado: (2022)

A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer
por: Kato, Yasuhiro, et al.
Publicado: (2019)

Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer
por: Okunaka, Mashiro, et al.
Publicado: (2020)

Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma
por: Wang, Hai-ying, et al.
Publicado: (2016)

Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy
por: Xu, Ziyi, et al.
Publicado: (2023)

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas
por: Tian, Zhichao, et al.
Publicado: (2022)

Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma
por: Hassan, Md Sazzad, et al.
Publicado: (2018)

Efficacy and safety profile of combining programmed cell death‐1 (PD‐1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non‐small cell lung cancer (NSCLC)
por: Xu, Ziyi, et al.
Publicado: (2021)

The efficacy and safety of nanoparticle albumin bound‐paclitaxel‐based regimen as second‐ or third‐line treatment in patients with advanced esophageal squamous cell carcinoma
por: Xin, Dao, et al.
Publicado: (2023)

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study
por: Yang, Guangjian, et al.
Publicado: (2022)

A Phase II Study of S-1 Monotherapy as a First-line Combination Therapy of S-1 Plus Cisplatin as a Second-line Therapy, and Weekly Paclitaxel Monotherapy as a Third-line Therapy in Patients with Advanced Gastric Carcinoma: A Second Report
por: Rino, Yasushi, et al.
Publicado: (2010)

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study
por: Zou, Zihua, et al.
Publicado: (2022)

Combination Therapy of Albumin-Bound Paclitaxel and Carboplatin as First Line Therapy in a Patient with Ovarian Cancer
por: Srinivasan, K. N, et al.
Publicado: (2014)

Clinical effect of pemetrexed as the first‐line treatment in Chinese patients with advanced anaplastic lymphoma kinase‐positive non‐small cell lung cancer
por: Ma, Di, et al.
Publicado: (2016)

Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration
por: Chen, Nianhang, et al.
Publicado: (2015)

Phase II Study of S-1 Monotherapy as a First-line, Combination Therapy of S-1 plus Cisplatin as a Second-line, and Weekly Paclitaxel Monotherapy as a Third-line Therapy in Patients with Advanced Gastric Carcinoma: Phase II Study of S-1, S-1 plus Cisplatin, and Weekly Paclitaxel in Patients with Advanced Gastric Carcinoma
por: Rino, Yasushi, et al.
Publicado: (2008)

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
por: Palumbo, Raffaella, et al.
Publicado: (2015)

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China
por: Zou, Zihua, et al.
Publicado: (2021)

Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer
por: Di Costanzo, Francesco, et al.
Publicado: (2009)

Albumin-bound paclitaxel in solid tumors: clinical development and future directions
por: Kundranda, Madappa N, et al.
Publicado: (2015)

Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Gelatin Methacryloyl Hydrogels Control the Localized Delivery of Albumin-Bound Paclitaxel
por: Vigata, Margaux, et al.
Publicado: (2020)

Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma
por: Takahashi, Akiko, et al.
Publicado: (2022)

Delivering albumin-bound paclitaxel across the blood-brain barrier for gliomas
por: Gould, Andrew, et al.
Publicado: (2021)

Concurrent chemotherapy and first‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first‐line treatment in advanced lung adenocarcinoma harboring an EGFR mutation
por: Xu, Ziyi, et al.
Publicado: (2021)

Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma
por: Shi, Yan, et al.
Publicado: (2013)

First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel
por: Gupta, Neha, et al.
Publicado: (2013)

Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)
por: Nakasya, Akio, et al.
Publicado: (2022)

Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302)
por: Shoji, Satoshi, et al.
Publicado: (2022)

Real world study of regimen containing bevacizumab as first‐line therapy in Chinese patients with advanced non‐small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

Real world study of the continuation of bevacizumab beyond disease progression after first‐line treatment containing bevacizumab in Chinese patients with advanced non‐small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

Albumin-bound formulation of paclitaxel (Abraxane(®) ABI-007) in the treatment of breast cancer
por: Miele, Evelina, et al.
Publicado: (2009)

Repetitive responses to nanoparticle albumin‐bound paclitaxel and carboplatin in malignant pleural mesothelioma
por: Kanai, Osamu, et al.
Publicado: (2016)

Superior Antitumor Activity of Nanoparticle Albumin-Bound Paclitaxel in Experimental Gastric Cancer
por: Zhang, Changhua, et al.
Publicado: (2013)

Tolerance, Variability and Pharmacokinetics of Albumin-Bound Paclitaxel in Chinese Breast Cancer Patients
por: Li, Qingmei, et al.
Publicado: (2018)

Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions
por: Giordano, Guido, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ftg83fcop4ifff3ktlsvkssqv0